Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-1000.06%
operating margin TTM
-1273.97%
revenue TTM
398.26 Million
revenue per share TTM
4.64$
valuation ratios | |
|---|---|
| pe ratio | -10.08 |
| peg ratio | 0.18 |
| price to book ratio | 1.91 |
| price to sales ratio | 102.54 |
| enterprise value multiple | -8.56 |
| price fair value | 1.91 |
profitability ratios | |
|---|---|
| gross profit margin | -227.47% |
| operating profit margin | -1273.97% |
| pretax profit margin | -990.27% |
| net profit margin | -1000.06% |
| return on assets | -16.34% |
| return on equity | -18.46% |
| return on capital employed | -21.66% |
liquidity ratio | |
|---|---|
| current ratio | 22.07 |
| quick ratio | 22.07 |
| cash ratio | 3.40 |
efficiency ratio | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 249.16 |
| days of payables outstanding | 44.77 |
| cash conversion cycle | 204.39 |
| receivables turnover | 1.46 |
| payables turnover | 8.15 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.10 |
| debt equity ratio | 0.12 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.10 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -0.64 |
cash flow ratios | |
|---|---|
| free cash flow per share | -1.71 |
| cash per share | 22.57 |
| operating cash flow per share | -1.69 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -0.64 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | -75.10 |
Frequently Asked Questions
When was the last time CRISPR Therapeutics AG (NASDAQ:CRSP) reported earnings?
CRISPR Therapeutics AG (CRSP) published its most recent earnings results on 05-11-2024.
What is CRISPR Therapeutics AG's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. CRISPR Therapeutics AG (NASDAQ:CRSP)'s trailing twelve months ROE is -18.46%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. CRISPR Therapeutics AG (CRSP) currently has a ROA of -16.34%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CRSP's net profit margin stand at?
CRSP reported a profit margin of -1000.06% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CRSP's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 22.07 in the most recent quarter. The quick ratio stood at 22.07, with a Debt/Eq ratio of 0.12.